Clinical trials: Biochemically Recurrent Prostate Carcinoma
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
This prospective pilot study will assess the feasibility of rh PSMA 7.3 positron emission tomography/magnetic resonance imaging (PET/MRI) scans in detecting prostate cancer that may have come back (recurrent) in patients with…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT04978675
- Testing
- Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
This phase II trial studies how well androgen deprivation therapy and apalutamide with or without radiation therapy works for the treatment of prostate cancer that has a rise in the blood level of prostate-specific antigen (PSA)…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT04585932
- Testing
- Apalutamide, Degarelix, Leuprolide Acetate
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT06205316
- Testing
- Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 118 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Background: Some people with prostate cancer have a rise in prostate-specific antigen (PSA). This can happen even after treatments like radiation and surgery.
- Trial name
- NCT03315871
- Testing
- Antigen direct immunotherapy: PROSTVAC-V, Antigen direct immunotherapy: PROSTVAC-F, MSB0011359C (M7824)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer Recurrent, Prostate Cancer
Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
The purpose of this phase I/Ib study is to determine the safety profile of Epidiolex (CBD oil) in biochemically recurrent prostate cancer patients. The study consists of a dose escalation part and dose expansion part.
- Conditions
- Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT04428203
- Testing
- Epidiolex Oral Liquid Product
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Zin W Myint
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with…
- Conditions
- High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
- Trial name
- CHARTER (NCT05437679)
- Testing
- Blood collection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Angle plc
Prostate Cancer
External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)
This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent…
- Trial name
- NCT05146973
- Testing
- 177Lu-DOTA-TLX591
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA…
- Conditions
- Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
- Trial name
- NCT05847348
- Testing
- 68Ga-PSMA-11, PET/CT or PET/MRI
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
This phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in detecting the spread of cancer to the bones (bone metastasis) in patients with prostate cancer and increased…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Trial name
- NCT04928820
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Olaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a…
- Trial name
- NCT03047135
- Testing
- Olaparib
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Prostate Cancer
Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer
RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid…
- Trial name
- NCT00313534
- Testing
- masoprocol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer
Recent pre-clinical work has suggested that Itraconazole has an anti-cancer effect that works synergistically with hydroxychloroquine.
- Trial name
- HITMAN-PC (NCT03513211)
- Testing
- SUBA-itraconazole, Hydroxychloroquine
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- St Vincent's Hospital, Sydney
Prostate Adenocarcinoma
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate cancer (PC) remains the most-common non-cutaneous cancer diagnosed in American males, accounting for an estimated 174,560 estimated new cases and 31,620 estimated deaths in 2019.
- Trial name
- NCT02624518
- Testing
- 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Andrei Iagaru
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
This phase II trial studies how well an exercise program and continuous Fitbit monitoring work for managing metabolic syndrome and cardiovascular disease risk in patients with prostate cancer that has spread to other places in…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT05054296
- Testing
- Educational Intervention, Exercise Intervention, FitBit
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
Ga-68-PSMA-11 in Men With Prostate Cancer
The purpose of this study is to provide access to Ga-68-PSMA-11 PET for evaluation of male veterans with newly diagnosed or biochemically recurrent prostate cancer.
- Trial name
- Ga68-PSMA-11 (NCT05744115)
- Testing
- Ga-68-PSMA-11
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Timothy Hoffman
Prostate Cancer
GM-CSF in Treating Patients With Relapsed Prostate Cancer
RATIONALE: Colony stimulating factors, such as GM CSF, may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00908141
- Testing
- sargramostim
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Background: Some people who have been treated for prostate cancer still have high prostate-specific antigen (PSA) levels. This may indicate cancer.
- Trial name
- NCT02649439
- Testing
- PROSTVAC -V, PROSTVAC-F
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)